A 2018 study concluded that funding from the National Institutes of Health (NIH) “contributed to published research associated with every one of the 210 new drugs approved by the Food and Drug Administration from 2010–2016.
This is consistent with a broader fact of pharmaceutical development and research: the American public funds a great deal of research that is essential to pharmaceutical development, and in particular for breakthrough drugs. The price that Gilead charges for Truvada is particularly galling in view of the fact that the public, and not Gilead, paid for the research that first discovered, and then proved, that Truvada is effective as HIV PrEP. Robert Grant highlights, only 1 in 10 people who would benefit from PrEP are receiving it in the United States. The cost of Truvada creates a barrier to access. But Truvada does not need to be expensive: it costs less than $6 per month to manufacture, or less than 20 cents per pill. In the United States, Truvada is very expensive: Gilead charges over $2,000 per month average wholesale price, almost $70 per pill. Gilead does indeed charge an unreasonable price for Truvada, at least in the United States. We respectfully submit this letter to shed further light on these issues. We understand that the hearing will examine the taxpayer funding that led to approval by the Food and Drug Administration (FDA) of Truvada for PrEP and will address the issue of whether the public is receiving an appropriate return on its investment. (Gilead) for an HIV prevention drug known as Truvada, which is used for pre-exposure prophylaxis (PrEP).
We thank the Committee for holding a hearing on the issue of the unreasonable prices charged by Gilead Sciences, Inc.
He is a licensed patent attorney and holds a Ph.D. Her scholarship on prescription drugs has been published in high-profile journals, including the Journal of the American Medical Association, the New England Journal of Medicine, and the Yale Law Journal.Ĭhristopher Morten is a Fellow at GHJP and a Lecturer at Yale Law School, where he teaches in the Media Freedom and Information Access Clinic and litigates and researches matters promoting greater access to information on prescription drugs.
#House committee on oversight and reform how to#
She is an expert on the question of how to promote greater access to medicines and has studied, for over 15 years, the legal determinants of high prices for prescription drugs in the United States. She teaches and researches intellectual property law, international law, and global health. Among other projects, GHJP undertakes research and advocacy to ensure more integrity and transparency in clinical research and to bring about a more just system for the development and distribution of medicines.Īmy Kapczynski is Faculty Co-Director of GHJP and a Professor of Law at Yale Law School. GHJP is a program hosted jointly by Yale Law School and Yale School of Public Health that tackles contemporary problems at the interface of global health, human rights, and social justice. We write on behalf of the Yale Global Health Justice Partnership (GHJP). Re: Hearing on “HIV Prevention Drug: Billions in Corporate Profits after Millions in Taxpayer Investments”ĭear Chairman Cummings, Ranking Member Jordan, and members of the House Committee on Oversight and Reform : Ranking Member, House Committee on Oversight and ReformĪmy Kapczynski, Faculty Co-Director, Global Health Justice PartnershipĬhristopher Morten, Fellow, Global Health Justice Partnership Chairman, House Committee on Oversight and Reform
0 kommentar(er)
